Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with painkillers in advanced head and neck cancer
NCT06879691Phase 4Active, not recruiting
- Start
- May 2021
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC) (2 arms). Primary endpoint: Progression-Free Survival rate at 2 years. Started May 2021; status: active, not recruiting.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06879691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879691.